Abstract
Docetaxel has until recently been the only agent with a small survival benefit for metastatic castration-resistant prostate cancer (CRPC). To improve clinical outcome in CRPC, numerous classes of drugs targeting specific pathways involved in hormone action, bone metabolism, angiogenesis, apoptosis and immune response have currently been investigated concerning the efficacies of either single agents or combinations with docetaxel. Noteworthy, current two phase III trials of cabazitaxel and sipuleucel-T have demonstrated significant improvements of overall survival in CRPC. From the viewpoint of complexity of mechanisms implicated in prostate cancer progression, effective therapeutic strategies should be developed by multifaceted approaches, such as the composition of novel agents targeting for key molecules, cytotoxic chemotherapy, and immunotherapy. The recent patented molecules (e.g., hyaluronidase, caveolin, Bag1-L, N-cadherin, AR splicing variants, PCGEM-1) have a strong potential as therapeutic options for CRPC. Here, we review the newest evidence of novel agents and patented compounds and methods for the purpose of the future use in CRPC.
Keywords: AR splicing variants, Bag1-L, N-cadherin, Castration-resistant prostate cancer, hyaluronidase, caveolin, Novel Therapy, PCGEM-1, patents, target molecules
Recent Patents on Anti-Cancer Drug Discovery
Title: New Therapeutic Strategies for Castration-Resistant Prostate Cancer
Volume: 6 Issue: 3
Author(s): Tomoaki Tanaka and Tatsuya Nakatani
Affiliation:
Keywords: AR splicing variants, Bag1-L, N-cadherin, Castration-resistant prostate cancer, hyaluronidase, caveolin, Novel Therapy, PCGEM-1, patents, target molecules
Abstract: Docetaxel has until recently been the only agent with a small survival benefit for metastatic castration-resistant prostate cancer (CRPC). To improve clinical outcome in CRPC, numerous classes of drugs targeting specific pathways involved in hormone action, bone metabolism, angiogenesis, apoptosis and immune response have currently been investigated concerning the efficacies of either single agents or combinations with docetaxel. Noteworthy, current two phase III trials of cabazitaxel and sipuleucel-T have demonstrated significant improvements of overall survival in CRPC. From the viewpoint of complexity of mechanisms implicated in prostate cancer progression, effective therapeutic strategies should be developed by multifaceted approaches, such as the composition of novel agents targeting for key molecules, cytotoxic chemotherapy, and immunotherapy. The recent patented molecules (e.g., hyaluronidase, caveolin, Bag1-L, N-cadherin, AR splicing variants, PCGEM-1) have a strong potential as therapeutic options for CRPC. Here, we review the newest evidence of novel agents and patented compounds and methods for the purpose of the future use in CRPC.
Export Options
About this article
Cite this article as:
Tanaka Tomoaki and Nakatani Tatsuya, New Therapeutic Strategies for Castration-Resistant Prostate Cancer, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (3) . https://dx.doi.org/10.2174/157489211796957793
DOI https://dx.doi.org/10.2174/157489211796957793 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Current Pharmaceutical Design Mitochondrial Functionality and Chemical Compound Action on Sperm Function
Current Medicinal Chemistry Current and Future Applications of Probiotics
Current Nutrition & Food Science Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Exploring Novel Target Space: A Need to Partner High Throughput Docking and Ligand-Based Similarity Searches?
Combinatorial Chemistry & High Throughput Screening Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies in Genitourinary Cancers)
Current Drug Targets A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Role of TGF-β in Melanoma
Current Pharmaceutical Biotechnology Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Discovery of Novel <i>N</i>-alkyl 4-anilinofuro[2,3-<i>b</i>]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry